Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis
about
Therapies targeting cancer stem cells: Current trends and future challengesHarnessing the apoptotic programs in cancer stem-like cellsNovel delivery strategies for glioblastomaGlioma-derived cancer stem cells are hypersensitive to proteasomal inhibition.Direct Activation of Bax Protein for Cancer TherapyOpioid receptor activation triggering downregulation of cAMP improves effectiveness of anti-cancer drugs in treatment of glioblastomaCombination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemiaRocaglamide overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells by attenuating the inhibition of caspase-8 through cellular FLICE-like-inhibitory protein downregulation.Multi-analyte network markers for tumor prognosis.A functional yeast survival screen of tumor-derived cDNA libraries designed to identify anti-apoptotic mammalian oncogenes.Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis.Identification of non-canonical NF-κB signaling as a critical mediator of Smac mimetic-stimulated migration and invasion of glioblastoma cells.Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosisDiscovery and clinical introduction of first-in-class imipridone ONC201.Induction of the mitochondria-mediated apoptosis in human esophageal cancer cells by DS2, a newly synthetic diterpenoid analog, is regulated by Bax and caused by generation of reactive oxygen species.Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications.Targeting c-FLICE-like inhibitory protein (CFLAR) in cancer.Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma.Regulation of TRAIL-receptor expression by the ubiquitin-proteasome system.Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib.Identification of RIP1 as a critical mediator of Smac mimetic-mediated sensitization of glioblastoma cells for Drozitumab-induced apoptosis.Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.Bortezomib antagonizes microtubule-interfering drug-induced apoptosis by inhibiting G2/M transition and MCL-1 degradation.The DeISGylase USP18 limits TRAIL-induced apoptosis through the regulation of TRAIL levels: Cellular levels of TRAIL influences responsiveness to TRAIL-induced apoptosis.Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner.Bortezomib downregulates MGMT expression in T98G glioblastoma cells.ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells.Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells.KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL.Preclinical evaluation of bortezomib/dipyridamole novel combination as a potential therapeutic modality for hematologic malignancies.Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma MultiformeThe plant alkaloid and anti-leukemia drug homoharringtonine sensitizes resistant human colorectal carcinoma cells to TRAIL-induced apoptosis via multiple mechanisms.Specific expression of k63-linked ubiquitination of calmodulin-like protein 5 in breast cancer of premenopausal patients.Inhibition of O-GlcNAcase sensitizes apoptosis and reverses bortezomib resistance in mantle cell lymphoma through modification of truncated Bid.Cell death-based treatment of glioblastoma.Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma.TNFα promotes glioblastoma A172 cell mitochondrial apoptosis via augmenting mitochondrial fission and repression of MAPK–ERK–YAP signaling pathways
P2860
Q26777880-69CEDE15-4AE7-4D64-963F-1BCB8F27AE19Q26801037-29E7F2F4-F5BC-4D83-A219-AE19CBC4E843Q27006099-EC8854A5-6EF6-4480-AA21-B7923A7D4620Q30275189-25CA03B9-95DD-46A6-A510-80C33CF0CAC1Q30353924-BC70EAED-2DC2-4DB0-AF77-D653196546FBQ33728939-B87A8A51-4E6A-46EF-AE2E-B93CABD675F8Q33828073-18464871-359B-40EB-9995-9AC943478851Q34540808-E3288EBC-0B6C-46D3-9368-5B80227ABE08Q34541470-CA531FF9-CDF9-41FA-BAE9-09431788FF02Q34746484-A7199691-3C30-41DD-9AAD-C2A7A35DFF01Q35957393-56303D4A-1AD9-414D-9BC7-53FE8172094BQ36292020-12AE9A14-DE32-4EEC-ABDE-8D35A9F2BA58Q36738071-B259664E-E7D7-44A8-9457-4246A6923447Q37610475-8B356C36-CFDC-4126-9540-636974F233AEQ37687570-FF5C4CBC-4F1C-452A-B172-DF935D115F99Q37699216-6377F561-1744-4DD9-9800-E70D06AF61FDQ38021448-F4158553-53BC-4426-948D-9B21BF038EB8Q38068479-8235E9FA-8804-4FE4-BA28-C6F352EC29ADQ38111684-08AF0C51-ED4E-45A3-8153-64DBCCE49019Q38260461-DF61BA44-76C2-47EC-8A60-5FA982D2D24EQ38776733-0230F4BB-8F68-49D6-96C1-CCA1A69114ABQ38886482-3E738EE8-1CAA-407F-961D-3071762E86CEQ38945539-8E7B32FC-387B-44CD-AED7-F53CD2CBAF00Q39058933-4A426D6F-1222-424D-80E1-E2D3A16D421AQ39072507-CC847489-D07C-4C70-9B77-92B36EA34A8BQ39156092-B05A586E-3990-4FC7-808D-DEDAD6EB7AC5Q39207783-511FB23D-FC9C-4C3A-AB26-1DB3506FAF97Q39236559-49522D2A-2A7E-471B-AD51-2554A9F588B9Q39281860-F30E1108-760E-4762-9AB4-AEB8D5372FD5Q41084396-8CC09B68-58A3-48BB-BBE3-B0628B478E27Q41135739-5A20C9E7-6E69-426B-8320-E22AF4615DF5Q42577813-3BAADACE-B9DD-478E-B043-AC49D5EDCA23Q43468001-00F65B0D-1D30-4F56-9AE6-D1EDEBB84867Q43723696-FB0A1D4F-4EF4-4BB6-9937-A79EA50EE243Q45073732-9DDD1283-EB9A-44FA-BBC8-90505BD68C68Q48163001-97BCDAD2-E05D-48AF-8657-6EA9FCE4FE52Q48473042-B009C04D-9F83-4056-820B-39BD0078ED50Q58698788-BCEDF115-E401-4867-80A0-0903F7397C36
P2860
Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Bortezomib primes glioblastoma ...... ty and mitochondrial apoptosis
@ast
Bortezomib primes glioblastoma ...... ty and mitochondrial apoptosis
@en
Bortezomib primes glioblastoma ...... ty and mitochondrial apoptosis
@en-gb
Bortezomib primes glioblastoma ...... ty and mitochondrial apoptosis
@nl
type
label
Bortezomib primes glioblastoma ...... ty and mitochondrial apoptosis
@ast
Bortezomib primes glioblastoma ...... ty and mitochondrial apoptosis
@en
Bortezomib primes glioblastoma ...... ty and mitochondrial apoptosis
@en-gb
Bortezomib primes glioblastoma ...... ty and mitochondrial apoptosis
@nl
prefLabel
Bortezomib primes glioblastoma ...... ty and mitochondrial apoptosis
@ast
Bortezomib primes glioblastoma ...... ty and mitochondrial apoptosis
@en
Bortezomib primes glioblastoma ...... ty and mitochondrial apoptosis
@en-gb
Bortezomib primes glioblastoma ...... ty and mitochondrial apoptosis
@nl
P2093
P50
P921
P1476
Bortezomib primes glioblastoma ...... ty and mitochondrial apoptosis
@en
P2093
Lisa Nonnenmacher
Silvia Cristofanon
Sri Hari Krishna Vellanki
Thomas Unterkircher
P304
P356
10.1158/1078-0432.CCR-11-0075
P407
P577
2011-06-15T00:00:00Z